Zymeworks moves higher as Street cheers Ziihera regimen approval
Market reacted positively to the approval news regarding Ziihera therapy.
Entry price of $26.43 is positioned below the resistance level of $30.50 and above the support level of $21.52, representing a buy targeting a short-term rebound opportunity driven by the Ziihera approval news and surge in trading volume.
If RSI 70.1 is overbought and trading volume surges, take profit upon confirmed breakout above the $30.50 resistance level, and stop loss upon breakdown of the $21.52 support level — first-person simulation conditional.
RSI(14) at 70.1 is approaching overbought territory, the non-aligned moving average arrangement signals a trend reversal, trading volume at 3.79 times the 20-day average reflects sharply increased interest, and the 7-day change rate of +9.4% indicates a short-term bullish trend.
Predicted return target was +3.2%, but the actual result fell to -10.4%, confirming a loss as the price dropped below the stop-loss line of $21.52. Entry into the RSI overbought zone and declining trading volume were the key factors that caused the deviation from expectations.
In the next trade, I will avoid entering during the RSI 70.1 overbought zone and consider a staged buying strategy when the price approaches the support level of $21.52 with increased trading volume. The stop-loss will remain at the existing $21.52, while the take-profit is adjusted to partially sell when approaching the resistance level of $30.50.